Extended Data Table 1 Overall survival by genomic group

From: Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival

  1. OS by genomic group among all patients in the cohort considered for survival analysis (Methods, n = 2,270; left), and among patients who did not receive targeted treatment for actionable alterations (n = 2,187, right). Multivariable Cox proportional hazards model of OS, stratified by stage at diagnosis. Displayed P values are nominal two-sided P values associated with the observed hazard ratios from the multivariable regression models. HR, hazard ratio; CI, confidence interval. Bold numbers indicate P values <0.05.
Back to article page